A Lipoatrophic Syndrome Acquired in a Type 1 Diabetic Patient

Main Article Content

Jemai Chaima
Ben Mami Faika


Aims: Lipoatrophies can have multiple causes. Insulin lipoatrophies are among the rare causes. We report the case of patient with type 1 diabetes, with an acquired lipoatrophic syndrome.

Case Presentation: This was a 19-year-old patient who had been hospitalized in the Diabetology and Nutritional Diseases Department C of the National Nutrition Institute in Tunis for the balancing of diabetes. She has been known to have diabetes for 4 years under Neutral Protamine Hagedorn insulin (NPH insulin) basal bolus complet regimen. She had no other medical history including autoimmune. Her diabetes is poorly monitored, poorly balanced (HbA1C = 9.1%) and uncomplicated. The rotation of the injection sites was well performed by the patient. Her body mass index (BMI) was 19.2 kg/m2. The lipoatrophic lesions appeared a year ago and are found at the sites of insulin injection. Their sizes have been stable for 6 months. The lipid parameters were normal. The insulin requirement was 0.4 IU / kg / day. The therapeutic approach was to prohibit injections at the lesions installed, associated with local corticosteroid therapy. Regular monitoring of the progress of these lesions was planned.

Conclusion: This observation suggests that these lipodystophies are most likely of autoimmune origin. They cause diabetes imbalance in addition to their unsightly nature. The treatments currently used have not shown very good effectiveness, especially for extensive lesions already installed.

Diabetes, lipoatrohies, lipodistrophies, insulin.

Article Details

How to Cite
Chaima, J., & Mami Faika, B. (2020). A Lipoatrophic Syndrome Acquired in a Type 1 Diabetic Patient. Asian Journal of Research and Reports in Endocrinology, 2(2), 1-4. Retrieved from http://journalajrre.com/index.php/AJRRE/article/view/30101
Case Study


Jermendy G, Na´das J, Sa´ Pi Z. ‘‘Lipoblastoma-like’’ lipoatrophy induced by human insulin: morphological evidence for local dedifferentiation of adipocytes? Diabetologia. 2000;43:955–6.

Frid A, Hirsch L, Gaspar R, et al. The Third Injection Technique Workshop in Athens (TITAN). Diabetes Metab. 2010;36(Suppl. 2):S19-29.

Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39: 445-53.

Atlan-Gepner C, Bongrand P, Farnarier C. Insulin inducedlipoatrophy in type 1 diabetes: a possible tumor necrosisfactor-a-mediated dedifferentiation of adypocites, DiabetesCare 19. 1996;1283–85.

Jermendy G, Nadas J, Sa´ Pi Z, Lipoblastoma-likelipoatrophy induced by human insulin: morphologicalevidence for local dedifferentiation of adypocites, Diabetologia 43. 2000;955–56.

Rademecker RP, Pierard GE, Scheen AJ. Lypodistrophyreactions to insulin, Am. J. Clin. Dermatol. 8/1. 2007;27–28.

Shimizu I, Furuya K, Osawa H, Fujii Y, Makino H. A case ofinsulin-induced localized lobular panniculitis with evidencefor the phagocytosis of insulin by histiocytes, Endocr. J. 54/3. 2007; 477–80.

Rademecker RP, Pierard GE, Scheen AJ. Lypodistrophyreactions to insulin, Am. J. Clin. Dermatol. 8/1. 2007;27–28.

Ramos M. Farias. Human insulin-induced lipoatrophy: asuccessful treatment with glucocorticoid, Diabetes Care 29/4. 2000;926.

Lopez X, Castells M, Ricker A, et al. Human insulin analog--induced lipoatrophy. Diabetes Care. 2008;31: 442-4.

Griffin ME, Feder A, Tamborlane WV. Lipoatrophyassociated with lispro in insulin pump therapy, DiabetesCare 24. 2001; 174.